

Data Sheet

WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

 $\begin{tabular}{lll} \textbf{Product Name} & :MK256 \\ \textbf{Cat.No.} & :URK-V2376 \\ \textbf{CAS No.} & :2271348-04-8 \\ \textbf{Molecular Formula} & :C_{14}H_9BrN_2O_2 \\ \textbf{Molecular Weight} & :317.142 \\ \textbf{Target} & :AML \\ \textbf{Solubility} & : \\ \end{tabular}$

HO BI

Biological Activity

MK256 is a novel small molecules CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

MK256, a potent, selective, and orally available CDK8 inhibitor was developed to target AML.

MK256 inhibite proliferation of AML cell lines.

MK256 not only downregulated phosphorylated STAT1(S727) and STAT5(S726), but also lowered mRNA expressions of MCL-1 and CCL2 in AML cell lines.

References

[1] Jen-Chieh Lee, Shu Liu, et al. Oncotarget. 2022 Nov 2;13:1217-1236.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!